A non-inferiority trial about the efficacy, safety, and effect on QOL of weekly-DPP-4 inhibitor omarigliptin by the comparison with once-daily-DPP-4 inhibitor linagliptin in maintenance hemodialysis patients with type 2 diabetes.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Omarigliptin (Primary) ; Linagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2016 New trial record